App detects worsening heart failure for personalized case management

Researchers have demonstrated a smartphone application that monitors known heart failure by listening to patients’ voices for 30 seconds a day.

The app works by listening for subtle speaking patterns indicative of fluid in the lungs, the most common symptom of deteriorating cardiac function in these patients.

The research team presented its work online June 19 to the European Society of Cardiology, which has posted a news release describing the development.

Professor Offer Amir of Israel’s Hadassah Medical Centre and colleagues tested the system on 40 inpatients who’d been admitted with acute heart failure and lung congestion. The participants used smartphones to record five sentences two times—upon admission and just before discharge.

Amir and team found the app successful at distinguishing between pre-treatment (congested) and post-treatment (uncongested) states.

“Those with early signs of lung congestion could receive adjustments to their treatment, thereby preventing the need for hospitalization,” Amir says. “As more speech samples are obtained, the model becomes increasingly sensitive to changes.”

The study was funded by an Israeli AI startup, Cordio Medical, which developed the technology.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.